In this Australian Investors Podcast episode, Mitch sits down with Nick Sladen for a deep dive into Cogstate and why it may be one of the more compelling ASX healthcare names right now. Alzheimer's and broader central nervous system diseases are becoming more important as populations age, and Nick explains why that matters for Cogstate. The company plays a small but critical role in clinical trials, helping large pharmaceutical groups run cognitive testing with higher accuracy, cleaner data and stronger regulatory confidence. With more than 20 years of accumulated testing data, Cogstate has built an edge that is hard to replicate quickly. Mitch and Nick also unpack the numbers behind the bull case. They discuss strong margins, net cash, a share buyback, dividend flexibility and why AI could improve throughput rather than undermine the business model. The conversation also goes beyond Alzheimer's into rare disease, depression, schizophrenia and sleep trials, plus the role partnerships like Medidata could play in widening the opportunity set. They finish by testing the risks, including pharma spending cycles, execution, competition and the possibility that AI changes parts of the workflow over time. If you want a practical breakdown of a high-quality small-cap healthcare business with structural tailwinds, this episode is well worth your time. Episode resources Speak with the Rask Advice team Ask a question (select the Investors podcast) Show partner resources ETF investor? Go beyond ordinary with Global X: View all funds Visit TermPlus to learn more Have the chance to win a 5k travel voucher. Take the TermPlus survey here (last entry 31st of May) Rask Resources All services Financial Planning Invest with us Access Show Notes Ask a question We love feedback! Follow us on social media: Instagram: @rask.invest TikTok: @rask.invest DISCLAIMER: This podcast contains general financial information only. That means the information does not take into account your objectives, financial situation, or needs. Because of that, you should consider if the information is appropriate to you and your needs, before acting on it. If you’re confused about what that means or what your needs are, you should always consult a licensed and trusted financial planner. Unfortunately, we cannot guarantee the accuracy of the information in this podcast, including any financial, taxation, and/or legal information. Remember, past performance is not a reliable indicator of future performance. The Rask Group is NOT a qualified tax accountant, financial (tax) adviser, or financial adviser. Access The Rask Group's Financial Services Guide (FSG): https://www.rask.com.au/fsg Learn more about your ad choices. Visit megaphone.fm/adchoices

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related